Scarica l'app Stockscreener
1.98
7.04%
-0.15
Dopo l'orario di chiusura:
1.96
-0.02
-1.01%
Celularity Inc Borsa (CELU) Ultime notizie
How sentiment analysis helps forecast Celularity Inc.Earnings Performance Report & Growth Focused Stock Reports - newser.com
Using Python tools to backtest Celularity Inc. Equity Warrant strategiesAnalyst Upgrade & Daily Profit Focused Stock Screening - newser.com
Candlestick signals on Celularity Inc. stock todayRate Cut & Low Risk Growth Stock Ideas - newser.com
How to recover losses in Celularity Inc. Equity Warrant stockWeekly Trade Analysis & Capital Efficiency Focused Ideas - newser.com
How Celularity Inc. stock performs during Fed tightening cyclesPortfolio Profit Report & Technical Entry and Exit Alerts - newser.com
Celularity Inc. Equity Warrant stock trendline breakdown2025 Geopolitical Influence & AI Based Buy/Sell Signal Reports - newser.com
Celularity Inc. Equity Warrant stock outlook for YEARQuarterly Portfolio Report & Low Risk Investment Opportunities - newser.com
What momentum shifts mean for Celularity Inc. Equity WarrantWeekly Volume Report & Technical Pattern Recognition Alerts - newser.com
Is Celularity Inc. Equity Warrant stock supported by strong cash flowsQuarterly Trade Review & Technical Pattern Based Buy Signals - newser.com
Published on: 2025-10-15 11:28:29 - newser.com
Multi asset correlation models including Celularity Inc. Equity WarrantDividend Hike & Real-Time Stock Entry Alerts - newser.com
Applying big data sentiment scoring on Celularity Inc. Equity Warrant2025 Biggest Moves & Short-Term Trading Opportunity Alerts - newser.com
Can Celularity Inc. Equity Warrant stock sustain market leadershipTrade Risk Assessment & Low Volatility Stock Suggestions - newser.com
Using data models to predict Celularity Inc. stock movementEntry Point & AI Forecasted Entry/Exit Points - newser.com
Is Celularity Inc. forming a bottoming baseBull Run & Real-Time Chart Breakout Alerts - newser.com
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease - Investing News Network
Evaluating Celularity Inc. with trendline analysisShare Buyback & Scalable Portfolio Growth Ideas - newser.com
Is Celularity Inc. Equity Warrant stock cheap at current valuationWeekly Profit Analysis & Community Supported Trade Ideas - newser.com
Celularity’s diabetic foot ulcer therapy shows promise in clinical trial By Investing.com - Investing.com Canada
Published on: 2025-10-14 13:50:00 - newser.com
Celularity’s diabetic foot ulcer therapy shows promise in clinical trial - Investing.com
Celularity Inc. Announces Positive Phase 2 Results for PDA-002 in Treating Diabetic Foot Ulcers Complicated by Peripheral Artery Disease - Quiver Quantitative
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease - Stock Titan
Is Celularity Inc. stock cheap at current valuationJuly 2025 Closing Moves & Weekly High Return Forecasts - newser.com
How to track smart money flows in Celularity Inc. Equity Warrant2025 Big Picture & Verified Entry Point Signals - newser.com
Celularity Inc. Equity Warrant recovery potential after sell off2025 Earnings Surprises & Community Consensus Trade Alerts - newser.com
Published on: 2025-10-14 00:55:53 - newser.com
Analyzing Celularity Inc. with multi timeframe charts2025 Market Sentiment & Weekly High Return Opportunities - newser.com
Can Celularity Inc. stock hit analyst price targetsJuly 2025 PreEarnings & Real-Time Price Movement Reports - newser.com
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):